GSK, Chroma in potential $1B deal over anti-inflammatory drugs

06/23/2009 | Reuters

GlaxoSmithKline is teaming up with Chroma Therapeutics to secure rights to the latter's small-molecule compounds that target macrophages to treat inflammatory diseases such as rheumatoid arthritis. Chroma could receive more than $1 billion out of the deal depending on the success of the four drug programs, which employ its proprietary esterase-sensitive motif technology to enhance drug delivery.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX